- Report
- February 2026
- 211 Pages
Global
From €4327EUR$4,850USD£3,746GBP
- Report
- November 2025
- 200 Pages
Global
From €7092EUR$7,950USD£6,140GBP
- Report
- June 2025
- 200 Pages
Global
From €2488EUR$2,789USD£2,154GBP
- Clinical Trials
- April 2025
- 80 Pages
Global
From €1784EUR$2,000USD£1,545GBP
- Report
- February 2023
- 198 Pages
Global
From €6691EUR$7,500USD£5,793GBP
Tasimelteon is a drug used to treat circadian rhythm sleep disorders, such as Non-24-Hour Sleep-Wake Disorder (Non-24). It is a melatonin receptor agonist, meaning it works by mimicking the effects of the hormone melatonin. Tasimelteon is classified as a central nervous system (CNS) drug, and is used to help regulate the body's internal clock. It is approved by the U.S. Food and Drug Administration (FDA) for the treatment of Non-24 in adults who are totally blind.
Tasimelteon is part of a larger market of CNS drugs, which includes medications used to treat a variety of neurological conditions, such as depression, anxiety, and insomnia. These drugs are used to help regulate the brain's activity and improve mental health.
Some companies in the Tasimelteon market include Vanda Pharmaceuticals, which manufactures and markets the drug, as well as other pharmaceutical companies that produce generic versions of the drug. Additionally, there are a number of companies that specialize in the research and development of CNS drugs, such as Neurocrine Biosciences and Otsuka Pharmaceuticals. Show Less Read more